Year: 2023
Type: editorial
Abstract: Heart failure from ischemic heart disease is the leading cause of death, morbidity, and healthcare expenditure in the United States and worldwide.Mortality from time of diagnosis of heart failure is staggering-within five years, 50% of patients will have died 1 .Despite advances, mortality rates have improved modestly and the only cure for heart failure remains transplantation.Fewer than 4,000 transplants are performed in the United States annually.Over 200,000 patients are listed as eligible for heart transplantation and millions more die without listing 2 .Thus, novel therapies for heart failure are desperately needed.Towards this goal, in the current issue of Circulation, Tani et al report the therapeutic efficacy of cardiac reprogramming for chronic ischemic heart failure 3 .Through elegant in vivo proofof-concept studies, this work signals great promise for the future of reprogramming, and hope for a field eagerly awaiting translation of science-driven innovations to heart failure therapies.
Source: Circulation
Authors: Glynnis A. Garry, Eric N. Olson
Institution: The University of Texas Southwestern Medical Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4317033661